πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

IONIS PHARMACEUTICALS Patents

Full USPTO pharma patent portfolio for IONIS PHARMACEUTICALS β€” grant dates, expiration, and drug cross-links.

Patents
222
Expiring ≀24m
0

Quick answer

IONIS PHARMACEUTICALS has 222 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months β€” use filters for patent-cliff planning.

Page 1 of 5

  1. US 12410430

    Modulating apolipoprotein (A) expression

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12410225

    Modulation of dendritic cell lineages

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12409188

    Modulators of HSD17B13 expression

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12364753

    CD8 binding agents

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12351633

    PD-1 and PD-L1 binding agents

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12350285

    Compounds and methods for reducing ATXN3 expression

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12351614

    CLEC9A-based chimeric protein complexes

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12343357

    Compositions and methods for modulating MECP2 expression

    Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12297431

    Modulation of huntingtin expression

    Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12291709

    Compositions and methods for modulating apolipoprotein (a) expression

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12281305

    Compounds and methods for reducing prion expression

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12275940

    Conjugated antisense compounds and their use

    Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12241067

    Compounds and methods for reducing LRRK2 expression

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12227746

    Compounds and methods for modulating SCN2A

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12215321

    Modulators of diacyglycerol acyltransferase 2 (DGAT2)

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12188020

    Methods for reducing Ataxin-2 expression

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12180479

    Compounds and methods for modulating ATXN1

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12152244

    Selective antisense compounds and uses thereof

    Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12115225

    GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof

    Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12110491

    Selective reduction of allelic variants

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12091463

    Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH)

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12084497

    SIRP1Ξ± targeted chimeric proteins and uses thereof

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12043831

    Modulation of alpha synuclein expression

    Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12042510

    Modulators of IRF4 expression

    Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12030910

    Compounds and methods for the modulation of proteins

    Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12018261

    Compounds and methods for modulating factor XII

    Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11981897

    Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression

    Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11959080

    Methods and compositions for inhibiting PMP22 expression

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11926830

    Modulators of Complement Factor B

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11926825

    Compounds and methods for reducing ATXN2 expression

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11896643

    Fibroblast binding agents and use thereof

    Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11873495

    Compounds and methods for reducing LRRK2 expression

    Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11859180

    Antisense oligonucleotide compositions

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11851655

    Compositions and methods for modulating apolipoprotein (a) expression

    Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11840686

    Modulation of prekallikrein (PKK) expression

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11840689

    Method of treating fatty liver disease

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11834660

    Compositions for modulating Ataxin 2 expression

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11833168

    Compounds and methods for increasing STMN2 expression

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11833221

    Oligomeric compounds for reducing DMPK expression

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11786546

    Compounds and methods for modulating GFAP

    Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11781143

    Modulators of PNPLA3 expression

    Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11761000

    Compositions and their uses directed to huntingtin

    Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11753644

    Compounds and methods for reducing IFNAR1 expression

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11753463

    Therapeutic targeting of non-cellular structures

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11732265

    Compositions and methods for modulating complement factor B expression

    Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11725208

    Conjugated antisense compounds and their use

    Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11713462

    Modulation of GYS1 expression

    Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11702477

    Bi-functional chimeric proteins and uses thereof

    Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does IONIS PHARMACEUTICALS have?

222 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do IONIS PHARMACEUTICALS patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.